Mirion Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Installed-base nuclear demand is accelerating, with management seeing a decade or more of spending growth and broad opportunities in plant upgrades and new builds. Medical trends are improving, while margin accretion is expected to run at ~1 point annually or better, with updated guidance planned for early 2027.
-
Q3 orders and backlog surged, supporting raised FY organic revenue and cash flow guidance and expected mid- to high-teens Q4 organic growth. Margin pressure, front-loaded AI spending, and slower Medical growth temper the outlook, while nuclear fleet investment is a major demand driver.
-
Q2 2026 delivered strong order growth, expanding backlog, and higher adjusted EBITDA margins, driven by nuclear power momentum and large wins. Full-year guidance is maintained, with accelerating organic growth and margin expansion expected in the second half, supported by robust backlog and AI-driven innovation.
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved. No questions were raised during the Q&A, and risks related to forward-looking statements were noted.
-
Orders and backlog surged on strong nuclear and medical segment growth, with Paragon and Certrec acquisitions driving early synergies. Revenue and adjusted EBITDA rose year-over-year, and guidance remains confident for 2026, with margin expansion and robust nuclear demand expected.
-
Nuclear power drives nearly half of revenue, with strong growth in SMRs, international projects, and recurring installed base business. Margin expansion, robust backlog, and AI-driven productivity are key themes, while medical and nuclear medicine segments show continued growth potential.
Fiscal Year 2025
-
Record orders and strong growth in nuclear power and medicine drove 2025 results, with revenue up 7.5% and Adjusted EBITDA up 12%. 2026 guidance calls for 22%-24% revenue growth, margin expansion, and robust free cash flow, supported by recent acquisitions and a growing project pipeline.
-
Q3 revenue grew 8% year-over-year, led by strong nuclear power and medical segment performance. Adjusted EBITDA rose 15%, and free cash flow guidance was raised. Acquisitions and robust order growth position the business for continued momentum.
-
The acquisition expands nuclear market reach, especially in the U.S. and SMR segments, and is expected to be accretive to earnings in the first year. $10 million in annualized synergies are targeted, with integration over 18 months and a focus on recurring revenue and long-term growth.
-
Q2 2025 delivered strong revenue and EBITDA growth, driven by both nuclear and medical segments, with raised full-year guidance reflecting robust nuclear power demand and successful M&A. The Certrec acquisition and new digital platforms position the company for continued growth.
-
Q1 2025 saw strong organic revenue and order growth, margin expansion, and robust free cash flow. Guidance for 2025 was reaffirmed and raised for revenue, with tariff risks largely mitigated and strategic M&A activity continuing. Nuclear power momentum and disciplined execution support a positive outlook.
-
A global leader in ionizing radiation solutions, the company leverages its dominance in nuclear and medical markets to drive recurring revenue and capitalize on long-term trends in nuclear power and cancer care. Financial targets focus on free cash flow growth and disciplined M&A.
-
The company is positioned as a leader in ionizing radiation detection, with strong growth driven by nuclear power and healthcare trends. Margin expansion is expected through operational leverage and procurement, while a robust pipeline of large orders and renewed M&A activity support future growth. Capital allocation focuses on both organic and inorganic opportunities.
Fiscal Year 2024
-
Record 2024 results with double-digit Q4 growth, margin expansion, and strong backlog set the stage for continued growth in 2025. Nuclear and Safety led segment gains, while Medical faced China headwinds but showed resilience. Guidance calls for further revenue, margin, and cash flow improvements.
-
The company is leveraging its leadership in radiation detection across nuclear and medical markets, with strong recurring revenue from a global installed base and robust growth opportunities in new builds, SMRs, and digital services. Long-term targets include 6%-8% organic growth, 30% EBITDA margins, and significant free cash flow expansion by 2028.
-
Raised organic growth guidance to 6%-8% and committed to 30% EBITDA margins by 2028, driven by strong nuclear and medical market trends, digitalization, and innovation. Strategic partnerships, recurring revenue, and a robust M&A pipeline support long-term growth.
-
Q3 revenue grew 8% year-over-year, with margin expansion and strong performance in both nuclear and medical segments. Guidance for full-year adjusted EBITDA and EPS remains unchanged, while leverage continues to decline and the bid pipeline is robust, especially in nuclear power.
-
Q2 saw 5% revenue and 10.2% adjusted EBITDA growth, with margin expansion and strong Nuclear and Medical segment performance. Guidance was raised for adjusted EBITDA, and a major EDF partnership was signed, while international Medical headwinds are expected to ease in 2025.
-
A global leader in radiation detection, the firm leverages innovation and a strong market position across industrial and medical segments. The medical segment is rapidly growing, while nuclear power trends and new builds, especially in Europe and Asia, support long-term growth.